[1]孔维静,徐颖.综合干预措施下评估首次131I清甲治疗对分化型甲状腺癌患者唾液腺的慢性损伤[J].国际放射医学核医学杂志,2018,(1):30-35.[doi:10.3760/cma.j.issn.1673-4114.2018.01.006]
　Kong Weijing,Xu Ying.Assessment of the chronic injury of salivary glands in patients with differentiated thyroid cancer who underwent comprehensive intervention measures with first 131I clearing therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(1):30-35.[doi:10.3760/cma.j.issn.1673-4114.2018.01.006]
点击复制

综合干预措施下评估首次131I清甲治疗对分化型甲状腺癌患者唾液腺的慢性损伤(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第1期
页码:
30-35
栏目:
临床研究
出版日期:
2018-03-20

文章信息/Info

Title:
Assessment of the chronic injury of salivary glands in patients with differentiated thyroid cancer who underwent comprehensive intervention measures with first 131I clearing therapy
作者:
孔维静1; 2;  徐颖1
1. 671000, 大理大学临床医学院;
2. 617000, 攀枝花市中心医院核医学科
Author(s):
Kong Weijing1; 2;  Xu Ying1
1. School of Clinical Medicine, Dali University, Dali 671000, China;
2. Department of Nuclear Medicine, Panzhihua Central Hospital, Panzhihua 617000, China
关键词:
分化型甲状腺癌; 99m锝高锝酸钠; 碘放射性同位素; 清甲; 唾液腺; 体层摄影术; 发射型计算机; 单光子; 体层摄影术; X线计算机
Keywords:
Differentiated thyroid carcinoma; Sodium pertechnetate Tc99m; Iodine radioisotopes; Thyroid remnant ablation; Salivary glands; Tomography; emission-computed; single-photon; Tomography; X-ray computed
DOI:
10.3760/cma.j.issn.1673-4114.2018.01.006
摘要:
目的 研究探讨分化型甲状腺癌（DTC）患者在采取综合干预措施后首次131I清甲治疗对唾液腺功能的慢性损伤情况。方法 选取2016年8月至2017年9月在攀枝花市中心医院核医学科首次行131I（4200.24±604.21） MBq清甲治疗的DTC患者52例，所有患者均在131I清甲治疗后立即采取综合干预措施（饮食护理、心理护理、物理护理、口腔卫生护理、健康宣教及药物治疗等），并分别于131I清甲前和治疗后6个月行99TcmO4-唾液腺动态显像，计算其摄取峰值和排泌分数，所得数据采用自身配对t检验分析，同时联合口干评分法评估唾液腺功能的损伤情况。结果 （1）左侧腮腺摄取峰值在131I清甲前为45.157±19.421，治疗后6个月为52.600±21.716，差异有统计学意义（t=2.470，P=0.018）。（2）右侧腮腺、双侧颌下腺的摄取峰值及双侧腮腺、双侧颌下腺的排泌分数之间的差异均无统计学意义（t=0.784、0.524、0.514、0.362、0.731、0.596、0.507，均P>0.05）。（3）对52例患者行问卷调查和口干评分法分析，其中，50例（96.2%）患者无口干症状，仅有2例（3.8%）出现轻度口干症状。结论 （1）首次131I清甲治疗可引起DTC患者唾液腺功能受损，损伤主要以单侧腮腺摄取功能为主，呈非对称性损伤。双侧颌下腺的摄取和排泌功能则未受到明显影响。（2）症状上，在综合干预保护措施下，绝大部分患者在接受首次131I清甲治疗后6个月无明显口干情况，生活质量无明显影响。
Abstract:
Objective To study the effect of first time 131I clearance therapy on chronic salivary gland function in patients with differentiated thyroid cancer(DTC) after comprehensive intervention. Methods Fifty-two cases of DTC patients who were treated with 131I[(4200.24±604.21) MBq] clearance for the first time in the Department of Nuclear Medicine in Panzhihua Central Hospital were selected from August 2016 to September 2017. All patients were treated with 131I clearance immediately after the comprehensive intervention (diet nursing, psychological nursing, physical nursing, oral health care, health education, and drug therapy) and before and 6 months after treatment. Moreover, patients underwent 99TcmO4- salivary gland scintigraphy, and the peak uptake and excretion fraction(%) were calculated. The obtained data were analyzed by self-compared t test. The dry mouth scores of salivary gland function damage were also evaluated. Results (1) The peak uptake of the left parotid gland before 131I clearance and after 6 months of treatment was 45.157±19.421 and 52.600±21.716, respectively. The difference was statistically significant (t=2.470, P=0.018). (2) No significant difference was observed in the peak values between the right parotid and bilateral submandibular gland and between the bilateral parotid and bilateral submandibular glands(t=0.784, 0.524, 0.514, 0.362, 0.731, 0.596, 0.507, all P>0.05). (3) Fifty-two patients were analyzed by using questionnaires and dry mouth scores. Result showed that 50 cases(96.2%) indicated no xerostomia, and only two cases (3.8%) presented mild xerostomia. Conclusions (1) The first 131I treatment can cause salivary gland dysfunction in patients with DTC. This damage is mainly unilateral parotid gland uptake, which is an asymmetrical injury. Additionally, the uptake and excretory function of bilateral submandibular glands are not significantly affected. (2) Approximately 96.2% patients showed no significant dry mouth after receiving 131I clearance treatment for 6 months. Therefore, the intervention exerted significant effects on the quality of life of patients.

参考文献/References:

[1] 宋润波, 孟增智, 贾清雨. 分化型甲状腺癌的治疗新进展[J]. 现代中西医结合杂志, 2015, 24(24):2728-2730. DOI:10.3969/j.issn.1008-8849.2015.24.043. Song RB, Meng ZZ, Jia QY. New progress in the treatment of differentiated thyroid carcinoma[J]. Modern J Integr Tradit Chin West Med, 2015, 24(24):2728-2730.
[2] Maruoka Y, Baba S, Isoda T, et al. A Functional Scoring System Based on Salivary Gland Scintigraphy for Evaluating Salivary Gland Dysfunction Secondary to 131I therapy in Patients with Differentiated Thyroid Carcinoma[J]. J Clin Diagn Res, 2017, 11(8):TC23-TC28. DOI:10.7860/JCDR/2017/27340.10431.
[3] Jonklaas J, Wang H, Esposito G. Salivary Function after Radioiodine Therapy:Poor Correlation between Symptoms and Salivary Scintigraphy[J/OL]. Front Endocrinol (Lausanne), 2015, 6:100[2017-11-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470264/. DOI:10.3389/fendo.2015.00100.
[4] 赵宁宁, 孙建梅, 李凤岐. 唾液腺显像检测131碘治疗对分化型甲状腺癌患者唾液腺功能的影响[J]. 潍坊医学院学报, 2015, 37(6):405-408. DOI:10.3969/j.issn.1004-3101.2015.06.002. Zhao NN, Sun JM, Li FQ. Influence of radioiodine treatment on the salivary glands evaluated by 99TcmO4- salivary glands dynamic imaging for the postoperative patients with DTC[J]. Acta Acad Med Weifang, 2015, 37(6):405-408.
[5] 姚红霞, 张金山, 袁文金. 唾液腺动态显像对口干患者唾液腺功能受损的诊断评价[J]. 影像诊断与介入放射学, 2014, 23(5):383-387. DOI:10.3969/j.issn.1005-8001.2014.05.005. Yao HX, Zhang JS, Yuan WJ. Scintigraphic evaluation of salivary gland function in patients with xerostomia[J]. Diagn Imaging Interventional Radiol, 2014, 23(5):383-387.
[6] 朱玉泉, 段东, 庞华, 等. 分化型甲状腺癌患者首次大剂量131I治疗后不同时间开始酸刺激对减少急性唾液腺损伤的研究[J]. 重庆医学, 2014, 43(22):2890-2892. DOI:10.3969/j.issn.1671-8348.2014.22.022. Zhu YQ, Duan D, Pang H, et al. Different beginning time of acid stimulation to reduce the acute damage of salivary glands after high-dose iodine-131 therapy for the post-surgery DTC patients[J]. Chongqing Med, 2014, 43(22):2890-2892.
[7] Van Nostrand D. Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer[J]. Oral Dis, 2011, 17(2):154-161. DOI:10.1111/j.1601-0825.2010.01726.x.
[8] 李伟, 汤日杰, 彭俊琴, 等. ROI和ADC值标准差在预测鼻咽癌近期疗效中的相关分析[J]. 中国临床医学影像杂志, 2017, 28(2):85-88. DOI:10.3969/j.issn.1008-1062.2017.02.003. Li W, Tang RJ, Peng JQ, et al. The analysis of ADC value’s standard deviation and ROI for prediction the short-term therapeutic effect in nasopharyngeal carcinoma[J]. J Chin Clin Med Imaging, 2017, 28(2):85-88.
[9] Orecchia R, Surgo A, Muto M, et al. VEROR radiotherapy for low burden cancer:789 patients with 957 lesions[J/OL]. Ecancermedicalscience, 2016, 10:677[2017-11-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27729942. DOI:10.3332/ecancer. 2016.677.
[10] Degener S, Pohle A, Strelow H, et al. Long-term experience of hyperbaric oxygen therapy for refractory radio-or chemotherapy-induced haemorrhagic cystitis[J/OL]. BMC Urol, 2015, 15:38[2017-11-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423090. DOI:10.1186/s12894-015-0035-4.
[11] Nunes LA, Mussavira S, Bindhu OS. Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid:a systematic review[J]. Biochem Med(Zagreb), 2015, 25(2):177-192. DOI:10.11613/BM.2015.018.
[12] Fallahi B, Beiki D, Abedi SM, et al. Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer?[J]. Nucl Med Commun, 2013, 34(8):777-786. DOI:10.1097/MNM.0b013e328362b1f2.
[13] Badam RK, Suram J, Babu DB, et al. Assessment of Salivary Gland Function Using Salivary Scintigraphy in Pre and Post Radioactive Iodine Therapy in Diagnosed Thyroid Carcinoma Patients[J]. J Clin Diagn Res, 2016, 10(1):ZC60-ZC62. DOI:10.7860/JCDR/2016/16091.7121.
[14] 张行涛, 苏莉, 黄诚刚, 等. 分化型甲状腺癌131I治疗后唾液腺损伤评价及预防[J]. 口腔医学研究, 2012, 28(5):472-475. Zhang XT, Su L, Huang CG, et al. The evaluation and prevention of the salivary gland toxicity of the differentiated thyroid carcinoma after 131I therapy[J]. J Oral Sci Res, 2012, 28(5):472-475.
[15] Upadhyaya A, Meng Z, Wang P, et al. Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer[J/OL]. Medicine(Baltimore), 2017, 96(25):e7164[2017-11-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484202. DOI:10.1097/MD.0000000000007164.
[16] 姚晓波, 金晓毛, 何静, 等. 131碘治疗甲状腺癌患者后唾液腺功能的变化分析[J]. 安徽医科大学学报, 2012, 47(1):67-71. DOI:10.3969/j.issn.1000-1492.2012.01.019. Yao XB, Jin XM, He J, et al. The variation of salivary gland function in patients with thyroid carcinoma after 131I treatment[J]. Acta Universitatis Medicinalis Anhui, 2012, 47(1):67-71.

相似文献/References:

[1]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[2]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[3]杨帆,袁卫红,张怡,等.99TcmO4-与99Tcm-HL91联合显像对甲状腺结节的诊断价值[J].国际放射医学核医学杂志,2009,33(5):261.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.002]
　YANG Fan,YUAN Wei-hong,ZHANG Yi,et al.Diagnosis of thyroid carcinoma using 99TcmO4-/99Tcm-HL91 imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(1):261.[doi:10.3760/cnla.j.issn.1673-4114.2009.05.002]
[4]叶智轶,王辉,吴靖川.维甲酸在诱导再分化治疗分化型甲状腺癌中的价值[J].国际放射医学核医学杂志,2007,31(4):221.
　YE Zhi-yi,WANG Hui,WU Jing-chuan.The value of retinoic acid-induced redifferentiation in the treatment of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(1):221.
[5]马寄晓,叶大铸.奥曲肽及其类似物用于肿瘤治疗的进展[J].国际放射医学核医学杂志,2005,29(2):79.
　MA Ji-xiao,YE Da-zhu.Advances in tumor treatment with labeled somatostatin analogues[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(1):79.
[6]罗全勇,朱瑞森.分化型甲状腺癌患者血清Tg和TgAb检测与结果分析应注意的问题[J].国际放射医学核医学杂志,2004,28(5):197.
　LUO Quan-yong,ZHU Rui-sen.Critical problems in the measurement and clinical evaluation of serum thyroglobulin and thyroglobulin antibody in differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(1):197.
[7]丁昊,叶斌,雷勇.增强DTC病灶摄取131I功能的措施[J].国际放射医学核医学杂志,2001,25(4):145.
　DING Hao,YIE Bin,LEI Yong.The augmentation of 131I uptake of DTC[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(1):145.
[8]康玉国.分化型甲状腺癌18F-FDG PET显像的临床应用[J].国际放射医学核医学杂志,2000,24(6):264.
　KANG Yuguo.Application of 18F-FDG PET scan in patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(1):264.
[9]陈可靖.甲状腺癌131I显像假阳性的分析及鉴别诊断[J].国际放射医学核医学杂志,2000,24(1):11.
　CHEN Ke-jing.The analysis and diferentiate diagnosis of false positive 131I imaging in metastatic thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(1):11.
[10]张渊琪,赵德善.分化型甲状腺癌的治疗进展[J].国际放射医学核医学杂志,2017,41(2):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
　Zhang Yuanqi,Zhao Deshan.Advances in the treatment of differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(1):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]

备注/Memo

备注/Memo:
收稿日期:2017-11-08。
通讯作者:徐颖,Email:Xy806nuclide@126.com
更新日期/Last Update: 2018-03-20